CANTON, Mass. and LAS VEGAS , Oct. 11, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO ), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine

CANTON, Mass. and VANCOUVER, British Columbia , Oct. 05, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO ), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and

CANTON, Mass. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO ), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today

NEW YORK , Sept. 06, 2019 (GLOBE NEWSWIRE) -- What: Organogenesis Holdings Inc. (Nasdaq: ORGO ), a leading regenerative medicine company, will visit the Nasdaq MarketSite in Times Square . In honor of the occasion, Gary S. Gillheeney, Sr. , President & CEO, will ring the Closing Bell.

Baylah Mazonson, 2019 Regenerative Medicine Scholarship Recipient, Will Attend Boston University This Fall CANTON, Mass. , Sept. 06, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO ), a leading regenerative medicine company focused on the development, manufacture, and

CANTON, Mass. , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO ) (the “Company”) announced today the completion of its previously announced exchange offer (the “Offer”) and consent solicitation relating to its publicly traded warrants.

CANTON, Mass. , Aug. 09, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO ), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today

CANTON, Mass. , July 22, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO ) (the “Company,” “we” or “our”) today announced that it has commenced an offer to exchange (“Offer to Exchange”) 0.095 shares of the Company’s Class A common stock (“Class A Common Stock”) for each

CANTON, Mass. , July 08, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO ), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today

CANTON, Mass. , July 01, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO ), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced